文献速递淋巴瘤

Avelumab治疗复发/难治性经典型霍奇金淋巴瘤:JAVELIN Hodgkins试验1b期结果

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
PubMed 文献 · Blood Adv · 2021-01-01

JAVELIN Hodgkins是一项1b期、多剂量、开放标签、随机、平行组试验,评估avelumab(抗PD-L1)在复发/难治性经典型霍奇金淋巴瘤(cHL)患者中的靶点占有率和药代动力学。总缓解率(ORR)为41.9%,完全缓解率19.4%,既往接受异基因造血干细胞移植(allo-HSCT)者ORR为55.6%。avelumab耐受性良好并在重度预处理cHL患者中显示抗肿瘤活性。

要点

  • avelumab在所有治疗组中靶点占有率均>90%,贯穿给药间期。
  • 全部随机患者ORR为41.9%,完全缓解率19.4%。
  • 既往allo-HSCT者ORR为55.6%,因allo-HSCT使用减少扩展期终止。

核心结论

  • avelumab在重度预处理的cHL患者中耐受性良好并显示抗肿瘤活性,提示PD-L1阻断可能足以产生治疗获益。

研究设计与样本

  • 研究4个剂量水平和2种给药方案:70、350、500 mg每2周;500 mg每3周;10 mg/kg每2周。
  • 主要终点为外周血免疫细胞中avelumab靶点占有率(按剂量/方案)和药代动力学参数;次要终点包括安全性和抗肿瘤活性。

主要发现

  • 所有治疗组靶点占有率>90%,贯穿给药间期;avelumab药代动力学数据与既往报道相似。
  • 任何级别最常见治疗相关不良事件:输液相关反应30.0%、恶心20.0%、丙氨酸氨基转移酶升高和皮疹各16.7%、乏力13.3%。
  • 全部随机患者ORR为41.9%,完全缓解率19.4%;既往接受allo-HSCT者ORR为55.6%。
  • 9例(29.0%)和20例(64.5%)分别接受过3线或≥4线既往抗癌治疗。

临床怎么用

  • avelumab在复发/难治性cHL中显示抗肿瘤活性,或可作为PD-L1阻断的治疗选择之一。
  • 因allo-HSCT使用减少,入组allo-HSCT后患者的扩展期已终止。

局限性

  • 因allo-HSCT使用减少,扩展期终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 9p24.1 chromosomal alteration in classical Hodgkin lymphoma (cHL) is associated with increased expression of programmed death ligand 1 (PD-L1)/PD-L2 and an immunosuppressive tumor microenvironment. Blockade of PD-L1/PD-1 interactions with avelumab (anti-PD-L1) is hypothesized to restore antitumor immunity. JAVELIN Hodgkins was a phase 1b, multiple-dose, open-label, randomized, parallel-arm trial of avelumab in patients with relapsed/refractory (R/R) cHL. Primary end points included avelumab target occupancy by dose/schedule in peripheral blood immune cells and pharmacokinetic parameters. Secondary end points included safety and antitumor activity. Four dose levels and 2 dosing schedules were investigated: 70, 350, and 500 mg administered every 2 weeks; 500 mg every 3 weeks; and 10 mg/kg every 2 weeks. Thirty-one patients with R/R cHL were randomized; 9 (29.0%) and 20 (64.5%) had received 3 or ≥4 prior anticancer treatments, respectively. Target occupancy of >90% was observed across all treatment arms, throughout the dosing interval. Avelumab pharmacokinetic data were similar to those previously reported. The most common treatment-related adverse events of any grade were infusion-related reaction (30.0%), nausea (20.0%), increased alanine aminotransferase and rash (16.7% each), and fatigue (13.3%). The objective response rate (ORR) in all randomized patients was 41.9%, with a complete response rate of 19.4%; ORR in those with prior allogeneic hematopoietic stem cell transplant (allo-HSCT) was 55.6%. Due to decreased use of allo-HSCT in patients with R/R cHL, the expansion phase enrolling post-allo-HSCT patients was terminated. Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with cHL, suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL. This trial was registered at www.clinicaltrials.gov as #NCT02603419.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Burton C, Radford J, et al. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv. 2021. PMID: 34477818. doi:10.1182/bloodadvances.2021004511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。